- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: evinacumab-dgnb | Evkeeza® | REGN1500
evinacumab is an approved drug (FDA (2021))
Compound class: Antibody
Comment: Evinacumab is a fully human monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3). Due to its role in lipid metabolism, ANGPTL3 is being investigated as a potential molecular target for the treatment of hypertriglyceridemia.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
A BLAST search of patented peptide sequences reveals that the heavy chain variable domain of evinacumab is identical to SEQ ID: NO 66 from patent US9018356 B2 , and the light chain variable region is identical to SEQ ID: NO 74 from the same patent (this heavy/light chain combination corresponds to antibody identifier H4H1276S).
Evinacumab utilises a different molecular mechanism compared to Regeneron's already approved anti-hyperlipidemic drug alirocumab (targets proprotein convertase subtilisin/kexin type 9).
|The affinity value in the table below represents antibody binding to full length human ANGPTL3. The corresponding Kd value for binding to the N-terminal coiled-coil domain of ANGPTL3 is reported as 0.66nM .|
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|